Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
Published inRheumatology, vol. 55, no. 2, p. 230-236
Publication date2016
Abstract
Keywords
- Antirheumatic Agents/therapeutic use
- Arthritis, Rheumatoid/drug therapy
- Disease Progression
- Europe
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Prospective Studies
- Registries
- Rituximab/therapeutic use
- Time Factors
- Treatment Outcome
Affiliation entities
Research groups
Citation (ISO format)
WALKER, Ulrich A et al. Rituximab done: what’s next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis. In: Rheumatology, 2016, vol. 55, n° 2, p. 230–236. doi: 10.1093/rheumatology/kev297
Main files (1)
Article (Published version)
Identifiers
- PID : unige:86816
- DOI : 10.1093/rheumatology/kev297
- PMID : 26316581
Journal ISSN1462-0324
